Melanoma driver mutations and immune therapy.

about

Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma.Emerging biomarkers for cancer immunotherapy in melanoma.Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.

P2860

Q45901589-456BAF72-80F9-4F27-8897-043CEE99BA81 Q50058145-FD0CE425-ED36-46BF-8474-033FB33DA548 Q51760444-5CCA1997-9D08-48DB-90FD-8B94DC1A10FD

P2860

Melanoma driver mutations and immune therapy.

Item

http://www.wikidata.org/entity/Q42034581

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Melanoma driver mutations and immune therapy.

@en

Melanoma driver mutations and immune therapy.

@nl

type

Item

label

Melanoma driver mutations and immune therapy.

@en

Melanoma driver mutations and immune therapy.

@nl

prefLabel

Melanoma driver mutations and immune therapy.

@en

Melanoma driver mutations and immune therapy.

@nl

P1476

Melanoma driver mutations and immune therapy.

@en

P2093

Douglas B Johnson

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Sosman

http://www.w3.org/2001/XMLSchema#string

Richard D Carvajal

http://www.w3.org/2001/XMLSchema#string

Ryan J Sullivan

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

NRAS mutation status is an independent prognostic factor in metastatic melanoma.

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Genetic basis for clinical response to CTLA-4 blockade in melanoma

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma

P304

e1051299

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/2162402X.2015.1051299

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christine M. Lovly

P577

2016-03-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27467925

http://www.w3.org/2001/XMLSchema#string

P932

4910708

http://www.w3.org/2001/XMLSchema#string

Melanoma driver mutations and immune therapy.

about

P2860

P2860

Melanoma driver mutations and immune therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932